夢潔股份(002397.SZ)擬設立湖南夢潔永創創業投資合夥企業 出資比例99.9%
格隆匯5月26日丨夢潔股份(002397.SZ)公佈,公司擬使用自有資金與湖南永創偉業投資管理有限公司(以下簡稱“永創偉業”)共同成立湖南夢潔永創創業投資合夥企業(有限合夥)。合夥企業擬出資總額為人民幣1億元,公司作為有限合夥人認繳出資人民幣9990萬元,認繳出資比例為99.90%;永創偉業作為普通合夥人認繳出資人民幣10萬元,認繳出資比例為0.10%。
合夥企業經營範圍:創業投資,從事非上市類股權投資活動及相關諮詢服務(不得從事吸收公眾存款或變相吸收公眾存款、集資收款、受託存款、發放貸款等國家金融監管及財政信用業務)。(依法須經批准的項目,經相關部門批准後方可開展經營活動)
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.